9-acetyl-6,9,11-trihydroxy-7-[[5-hydroxy-2-(2-hydroxypropyl)-4,10-dimethyl-4,5,6,6a,7,8,10,10a-octahydropyrano[3,4-d][1,3,6]dioxazocin-8-yl]oxy]-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione | 131443-34-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: 9-acetyl-6,9,11-trihydroxy-7-[[5-hydroxy-2-(2-hydroxypropyl)-4,10-dimethyl-4,5,6,6a,7,8,10,10a-octahydropyrano[3,4-d][1,3,6]dioxazocin-8-yl]oxy]-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
• CAS: 131443-34-0
• 化学式: C₃₄H₄₁NO₁₃
• 分子量: 671.7
• InChiKey: IYMKZHJAGBHDOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  48
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  211
• 氢给体数：
  6
• 氢受体数：
  14

文献信息

• Hypoxia-Activated Anti-Cancer Agents
  申请人：Matteucci Mark

  公开号：US20080132458A1

  公开（公告）日：2008-06-05

  Prodrugs of cyclic anthracyclin toxins comprising a hypoxia-activated trigger and are disclosed. In addition, methods of treating cancer using the compounds of the invention are disclosed.

  环蒽毒素的前药包括一个缺氧活化触发器，并且已经披露。此外，还披露了使用该发明化合物治疗癌症的方法。
• Substituted aryl-amine derivatives and methods of use
  申请人：Yuan Chenguang Chester

  公开号：US20060040966A1

  公开（公告）日：2006-02-23

  Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds of Formula I and II wherein R, R 1 and R 2 for each formula are defined herein. The invention further includes analogs, prodrugs and pharmaceutically acceptable salts and derivatives of Formulas I and II, as well as pharmaceutical compositions, medicaments and methods thereof for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的胺类化合物对于预防和治疗由血管生成介导的疾病等疾病有效。该发明涵盖了式I和式II的新型化合物，其中每个式中的R、R1和R2如本文所定义。该发明还包括式I和式II的类似物、前药和药物可接受的盐和衍生物，以及用于预防和治疗涉及癌症等疾病和其他疾病或病症的药物组合物、药物和方法。该发明还涉及制备这种化合物的工艺以及在这种工艺中有用的中间体。
• Specific binding agents to hepatocyte growth factor
  申请人：Amgen, Inc

  公开号：EP2341067A1

  公开（公告）日：2011-07-06

  Specific binding agents that interact with hepatocyte growth factor (HGF) are described. Methods of treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF are described. Methods of detecting the amount of HGF in a sample using a specific binding agent to HGF are described.

  描述了与肝细胞生长因子（HGF）相互作用的特异性结合剂。描述了通过施用药学有效量的 HGF 特异性结合剂治疗癌症的方法。介绍了使用与 HGF 的特异性结合剂检测样品中 HGF 含量的方法。
• Human c-fms antigen binding proteins
  申请人：Amgen, Inc

  公开号：EP2589610A1

  公开（公告）日：2013-05-08

  Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-I, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.

  提供了与人类 c-fms 蛋白结合的抗原结合蛋白。还提供了编码抗原结合蛋白的核酸、载体和细胞。抗原结合蛋白可抑制 c-fms 与 CSF-I 的结合，减少单核细胞向肿瘤的迁移，并减少肿瘤相关巨噬细胞的聚集。
• Angiopoietin-2 specific binding agents
  申请人：Oliner Daniel Jonathan

  公开号：US20060018909A1

  公开（公告）日：2006-01-26

  Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

  公开了与血管生成素-2 结合的特异性结合剂，如全人类抗体。还公开了抗体的重链片段、轻链片段和 CDR，以及制造和使用抗体的方法。